Document is current
Any future updates will be listed below
-
Authors
Mayer, Kenneth H. https://orcid.org/0000-0001-7460-733X
Yuhas, Krista
Amico, K. Rivet
Wilkin, Timothy
Landovitz, Raphael J.
Richardson, Paul
Marzinke, Mark A.
Hendrix, Craig . W
Eshleman, Susan H.
Cottle, Leslie M.
Marcus, Cheryl
Chege, Wairimu
Rinehart, Alex R.
Rooney, James F.
Andrew, Philip
Salata, Robert A.
Magnus, Manya
Farley, Jason E.
Liu, Albert Y.
Frank, Ian
Ho, Ken
Santana, Jorge
Stekler, Joanne D.
Chen, Ying Q.
McCauley, Marybeth
Gulick, Roy M.
,
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (UM1AI069412)
- License Information
-
More Information
Article History
Accepted: 26 May 2022
First Online: 10 June 2022
Declarations
:
: Dr. Mayer has received research grant funding from Gilead Sciences and Merck, Inc, and has served on scientific advisory boards for Gilead Sciences, Merck, and ViiV.
: The protocol was approved by the Institutional Review Boards of all of the participating sites.
: All participants were educated about the protocol by study staff who were trained by the HPTN for the conduct of the trial, and then reviewed an IRB approved informed consent document. If they felt that their questions were addressed and wanted to participate in the study, they then were asked to sign the document.
: Study protocol prohibited the sharing of individual data. Participants agreed to allow for sharing of de-identified data with the Statistical Data Management Center of the HPTN, at the Fred Hutchinson Cancer Center.
